drugset
Drugs / Autologous bone marrow Stem Cell
last change Mar 2017 re-read 3 minutes ago

Autologous bone marrow Stem Cell

also known as BMSCs · bone marrow mononuclear stem cells

Cell therapy

Developed for
retinitis pigmentosa · stroke disorder
Investigated by
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Hospital Universitario Virgen de la Arrixaca · Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca · Manipal Acunova Ltd. · Ministry of Science and Technology, India · Public Health Service, Murcia
+2 more · Red de Terapia Celular · Spanish National Health System

Trials 2

today NCT02280135 · Ph 1 NCT01501773 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02280135 Nov 2014 → Mar 2017 retinitis pigmentosa Red de Terapia Celular Completed No outcome recorded
Phase 21 trial · 1 missed
Phase 2 NCT01501773 Oct 2008 → Oct 2011 stroke disorder Manipal Acunova Ltd. Completed Missed primary

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Autologous bone marrow stem cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT01501773 ↗
1

NCT02280135 ↗
Known as BMSCs “Pilot studies have suggested benefit from intravenous administration of bone marrow mononuclear stem cells (BMSCs) in stroke.” PMID 25378424 ↗ Nov 2014
Known as bone marrow mononuclear stem cells “Pilot studies have suggested benefit from intravenous administration of bone marrow mononuclear stem cells (BMSCs) in stroke.” PMID 25378424 ↗ Nov 2014
Modality Cell therapy “stem cell therapy” NCT01501773 ↗
Route Intravenous “intravenous infusion of autologous BMSCs” PMID 25378424 ↗ Nov 2014